A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for recurrent glioblastoma

Trial Profile

A proof of concept clinical trial assessing the safety of the coordinated undermining of survival paths by 9 repurposed drugs combined with metronomic temozolomide (CUSP9v3 Treatment Protocol) for recurrent glioblastoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 15 Jun 2017

At a glance

  • Drugs Aprepitant (Primary) ; Auranofin (Primary) ; Captopril (Primary) ; Celecoxib (Primary) ; Disulfiram (Primary) ; Itraconazole (Primary) ; Minocycline (Primary) ; Ritonavir (Primary) ; Sertraline (Primary) ; Temozolomide (Primary)
  • Indications Glioblastoma
  • Focus Adverse reactions; Proof of concept
  • Most Recent Events

    • 09 May 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top